Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Operating Leases: 2019-2024

Historic Operating Leases for Zevra Therapeutics (ZVRA) over the last 6 years, with Dec 2024 value amounting to $792,000.

  • Zevra Therapeutics' Operating Leases rose 191.30% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 191.30%. This contributed to the annual value of $792,000 for FY2024, which is 73.68% up from last year.
  • As of FY2024, Zevra Therapeutics' Operating Leases stood at $792,000, which was up 73.68% from $456,000 recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Operating Leases registered a high of $1.9 million during FY2020, and its lowest value of $456,000 during FY2023.
  • Moreover, its 3-year median value for Operating Leases was $792,000 (2024), whereas its average is $857,000.
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 65.53% in 2023, then spiked by 73.68% in 2024.
  • Yearly analysis of 5 years shows Zevra Therapeutics' Operating Leases stood at $1.9 million in 2020, then decreased by 17.03% to $1.6 million in 2021, then declined by 16.69% to $1.3 million in 2022, then tumbled by 65.53% to $456,000 in 2023, then skyrocketed by 73.68% to $792,000 in 2024.